Anzeige
Mehr »
Dienstag, 30.06.2026 - Börsentäglich über 12.000 News
Direkt neben Europas erster Lithium-Mine: Wartet hier der nächste Börsengewinner
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
171 Leser
Artikel bewerten:
(1)

NCQA Names Dr. Ari Robicsek as Inaugural Chief Medical Officer

Physician-scientist and healthcare analytics leader joins NCQA to advance digital quality measurement, data-driven innovation and patient-centered outcomes.

WASHINGTON, D.C. / ACCESS Newswire / June 30, 2026 / The National Committee for Quality Assurance (NCQA) today announced the appointment of Ari Robicsek, MD, as its inaugural Chief Medical Officer (CMO). Dr. Robicsek joined the organization on June 29, 2026, bringing more than two decades of experience at the intersection of clinical medicine, data science, healthcare analytics and innovation to deepen NCQA's clinical leadership and accelerate its quality modernization agenda.

"The creation of the CMO role reflects NCQA's commitment to meeting this moment in healthcare, as interoperable data, the rapid growth of AI and a shift toward outcomes that matter most to clinicians and patients continue to reshape the landscape," said Dr. Vivek Garg, NCQA President and CEO. "I am thrilled to welcome Dr. Robicsek to help lead this critical work. He is an accomplished physician-scientist whose experience building advanced analytics capabilities and translating data into actionable clinical insights makes him the ideal leader-not only to help us modernize quality measurement, but to define the next generation of digital, outcomes-focused quality infrastructure that better supports clinicians and patients."

Dr. Robicsek joins NCQA from Providence, where he served as Executive Vice President and Chief Analytics & Research Officer. There he led the system's data science, product development and research teams, and spearheaded the Value-Oriented Architecture (VOA) initiative - a framework that uses sophisticated data science to identify and disseminate care delivery patterns that improve quality, efficiency and consistency at scale. During his time at Providence, he also established the Providence Clinical Innovation Institute, raising millions of dollars to test digital technology and new models of care.

"NCQA has spent more than three decades building the quality infrastructure that American healthcare depends on. That legacy is extraordinary, and it is what drew me to this role," said Dr. Robicsek. "I am joining at what I believe is a pivotal moment for NCQA and for healthcare. The convergence of interoperable data, digital measurement capabilities and advances in AI creates an unprecedented opportunity to reimagine how we define, measure and improve quality. I am excited to help usher NCQA into a new era of quality measurement that is digitally enabled, scientifically rigorous, and, above all, more patient-centered."

Previously, Dr. Robicsek served as Vice President of Clinical Analytics and Associate Chief Medical Information Officer at NorthShore University HealthSystem, where his team received multiple national honors for information technology innovation. He is also the Founder and Chief Analytics & Research Officer of Arclight Intelligence, a healthcare innovation consulting firm.

A physician-scientist by training, Dr. Robicsek holds an MD from the University of Toronto and completed an Infectious Diseases Fellowship at Harvard Medical School. He has authored and co-authored more than 130 academic publications with over 15,000 citations, including work published in Nature and JAMA. He is an inventor on patents related to clinical decision support systems.

About NCQA

NCQA is an independent nonprofit organization that defines and drives healthcare quality through accreditation, standards, performance measurement, and expert support. For more than 35 years, NCQA has advanced transparency, accountability, and enabled healthcare organizations to deliver better outcomes for patients. NCQA's Healthcare Effectiveness Data and Information Set (HEDIS1) is one of healthcare's most widely used performance improvement tools. Learn more at ncqa.org. Follow NCQA on X @ncqa and on LinkedIn linkedin.com/company/ncqa.

# # #

Media Contact
SHIFT Communications
NCQA@shiftcomm.com

1 HEDIS is a registered trademark of the National Committee for Quality Assurance (NCQA).

SOURCE: NCQA



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/ncqa-names-dr.-ari-robicsek-as-inaugural-chief-medical-officer-1184028

© 2026 ACCESS Newswire
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.